US-based Cirena has formally launched following the successful delivery of high-purity long RNA to academic and pharmaceutical research teams in the US, Europe and Japan.
The company specialises in the synthesis of long and ultra-long RNA constructs, targeting a key challenge in advanced CRISPR and genome-editing workflows.
As CRISPR, base editing and prime editing applications continue to evolve, researchers are increasingly exploring longer guide RNAs to improve editing efficiency and reduce off-target effects.
However, producing long RNA, typically in the 100–400 nucleotide range, has historically required complex ligation strategies, extensive purification or long lead times.
Cirena’s proprietary synthesis technology enables the rapid production of long RNA while maintaining high sequence integrity and purity.
According to the company, reduced turnaround times allow researchers to iterate gRNA, pegRNA and related designs more quickly, supporting applications including oncology research, vaccine development and gene regulation studies.
“As RNA science evolves, researchers are eager to unlock the potential of longer gRNAs for improved editing precision,” said Marv Caruthers, founder of Cirena.
“Cirena enables this exploration by delivering high-quality long RNA rapidly, eliminating delays that have historically slowed innovation.”
John Rinn, CEO of LincSwitch, commented that Cirena had demonstrated reliable delivery of 150-nucleotide RNA with consistent quality, enabling research teams to advance experiments without disruption.
Separately, Sweden-based Epigenica AB has launched its EpiFinder Analysis Service, a fully managed, high-throughput platform designed to simplify epigenomic research by managing the complete workflow from study design to final data delivery.
Based at Epigenica’s facility in Solna, the service supports both small- and large-scale projects, with the capacity to process hundreds of samples per week.
Automated laboratory processing is combined with standardised bioinformatics pipelines to deliver parallel profiling of histone modifications and DNA methylation with high reproducibility.
The company also provides downstream scientific support, including biological interpretation, data visualisation and guidance on multiomics data integration. Turnaround times range from 3–6 weeks.
According to Epigenica, the service is intended to reduce operational complexity and technical variability, allowing researchers to focus on biological insights rather than workflow management.